Literature DB >> 15212656

Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.

Francesco Minuto1, Eugenia Resmini, Mara Boschetti, Marica Arvigo, Maria Pia Sormani, Massimo Giusti, Diego Ferone, Antonina Barreca.   

Abstract

OBJECTIVE: It has been suggested that the threshold of 1 micro g/l of GH nadir after glucose load for definition of controlled acromegalic disease proposed in the 2000 consensus statement should be lowered to 0.30. We evaluated these two cut-off values in comparison with IGF-I, ALS and IGFBP-3 in a group of acromegalic patients. With the aim of simplifying the follow-up protocol in these patients we also tested if one single sample taken after glucose load could replace the nadir value. DESIGN AND MEASUREMENTS: GH secretion was evaluated by oral glucose tolerance test (OGTT), and by studying spontaneous secretion (GH day curve) with sampling at hourly intervals from 08.00 to 18.00 h; from the day curve, mean (MGHDC) and minimum (TRGH) values were considered. IGF-I, ALS, and IGFBP-3 were measured in the basal state at the first testing. patients Fifty acromegalic patients (26-83 years, 31 females, 19 males) in various phases of disease activity. Forty-two patients had previously undergone pituitary surgery (10 also radiotherapy), 23 were treated with SMS analogues and three with dopamine agonist drugs.
RESULTS: The nadir GH value after glucose load correlated most significantly with the 120th-minute sample (R = 0.95). Comparison of the postglucose 120th minute at the two cut-off values with IGF-I, IGFBP-3 and ALS showed higher concordance of postglucose level at 0.3 with IGF-I, while concordance was similar for the two cut-off values with ALS and IGFBP-3. When the 120th minute postglucose GH value is lower than 1 micro g/l and IGF-I is within 2SD for age nearly all other parameters are normal. IGF-I correlated more with ALS (R = 0.78) than with IGFBP-3 (R = 0.50) and the latter was less concordant with GH secretion parameters than the previous two.
CONCLUSIONS: A sample taken at the 120th minute after glucose load, together with IGF-I and/or ALS evaluation can give sufficient information for a routine assessment of disease activity, both in the diagnosis and in the follow-up to treatment. If GH is lower than 1 micro g/l and IGF-I/ALS are normal, then the patient can be classified as 'nonactive' or 'controlled'; a pathological IGF-I and/or ALS value is a sign of disease activity irrespective of the GH values, while normal IGF-I/ALS with an elevated GH requires further assessment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15212656     DOI: 10.1111/j.1365-2265.2004.02064.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.

Authors:  Susanna Bacigaluppi; Federico Gatto; Pasquale Anania; Nicola Luigi Bragazzi; Diego Criminelli Rossi; Giulia Benvegnu; Elena Nazzari; Renato Spaziante; Massimo Giusti; Diego Ferone; Gianluigi Zona
Journal:  Endocrine       Date:  2015-05-17       Impact factor: 3.633

2.  Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR.

Authors:  E Resmini; G Murialdo; M Giusti; M Boschetti; F Minuto; D Ferone
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

Review 3.  Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Authors:  Federico Gatto; Claudia Campana; Francesco Cocchiara; Giuliana Corica; Manuela Albertelli; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Massimo Giusti; Diego Ferone
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

4.  Daily life reflections of acromegaly guidelines.

Authors:  T Apaydin; H M Ozkaya; F E Keskin; O A Haliloglu; K Karababa; S Erdem; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2016-10-20       Impact factor: 4.256

5.  Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.

Authors:  M Scacchi; C Carzaniga; G Vitale; L M Fatti; F Pecori Giraldi; M Andrioli; A Cattaneo; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2011-06-21       Impact factor: 4.256

6.  Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience.

Authors:  Francesco M Minuto; Eugenia Resmini; Mara Boschetti; Alberto Rebora; Laura Fazzuoli; Marica Arvigo; Massimo Giusti; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 7.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 8.  Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.

Authors:  Laure Cazabat; Jean-Claude Souberbielle; Philippe Chanson
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 9.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 10.  Serum IGF-I levels in the diagnosis and monitoring of acromegaly.

Authors:  A M Brooke; W M Drake
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.